Quality of 56 medicines including Calcium-Vitamin D is bad, three fake medicines are being sold in the market. – ..

Counterfeit Medicines: The Central Drugs Standard Control Organization (CDSCO) has released the latest report for the month of October. There is a revelation in this which will blow your senses. Actually, 56 medicines of poor quality have been found in the market, including medicines for daily use. Apart from this, three fake medicines are also being sold indiscriminately in the market. Let us give you complete information about it.

what is the whole matter
As per regular regulatory monitoring activity, list of Non-Standard Quality (NSQ) and Counterfeit Medicines is released every month on CDSCO portal. According to the October report, 56 drug samples tested by central drug laboratories were found to be of substandard quality. Along with this, three medicines have also been found to be fake in the investigation.

The quality of these medicines is bad
It is noteworthy that this test is conducted every month by CDSCO, in which samples of medicines available in the market are tested. In the October list, 56 medicines were found to be of substandard quality, which included Calcium 500, Vitamin D3 250, IU Tablet IP, Ciprofloxacin Tablet USP 500, Aceclofenac, Paracetamol Tablet. At present the names of fake medicines have not been known.

Medicines were bad last month
After this investigation which is done every month, many medicines are revealed, after which the reaction of those companies also comes. The batches of medicines whose samples have been taken are available in the market for sale. Last month too, CDSCO’s September report found 49 medicines, including best-selling cough syrups, multivitamins, anti-allergies, etc., failed on quality standards. DCGI Rajiv Singh Raghuvanshi said that if a medicine fails on the testing criteria then it is not said to be of standard quality. This shows that the batch of the medicine of the company which has prepared this medicine is not as per the standard. Notices are issued to such companies.